SGN-CD228A / Pfizer - LARVOL DELTA

A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=88 | Terminated | Sponsor: Seagen Inc. | Trial completion date: Sep 2024 ➔ Mar 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Sep 2024 ➔ Mar 2023; Study closed due to portfolio prioritization

Metastases • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • EGFR • HER-2 • PD-L1

SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models. (PubMed, Mol Cancer Ther) - P1 | "Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity. SGN-CD228A is being investigated in an ongoing Phase I clinical trial (NCT04042480) in patients with advanced solid tumors."

Journal • Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • MFI2

A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=88 | Active, not recruiting | Sponsor: Seagen Inc. | Recruiting ➔ Active, not recruiting | N=210 ➔ 88

Enrollment change • Enrollment closed • Metastases • Breast Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • EGFR • HER-2 • PD-L1

A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=210; Recruiting; Sponsor: Seagen Inc.; Trial completion date: Jan 2023 ➔ Sep 2024; Trial primary completion date: Jan 2023 ➔ Sep 2024

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • EGFR • HER-2 • PD-L1

[VIRTUAL] SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors. (ASCO 2020) - P1 | "Enrollment is ongoing in the US and planned in Europe. Research Funding: Seattle Genetics Inc."

Clinical • P1 data • Breast Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • HER2 Negative Breast Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thoracic Cancer • MFI2

A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=240; Not yet recruiting; Sponsor: Seattle Genetics, Inc.

New P1 trial • Breast Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thoracic Cancer • EGFR • HER-2 • PD-L1

A Study of SGN-CD228A in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=240; Recruiting; Sponsor: Seattle Genetics, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Colorectal Cancer • Cutaneous Melanoma • Gastrointestinal Cancer • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thoracic Cancer • EGFR • HER-2 • PD-L1

[VIRTUAL] Utilizing PDX models to better understand factors that predict response to SGN-CD228A, an antibody drug-conjugate (ADC) for solid tumors (AACR-II 2020) - "Finally, we are utilizing RNAseq data to define a gene signature that may predict response to SGN-CD228A. In summary, we have found that SGN-CD228A is active in a diversity of solid tumor PDX models and biomarker data collected in these studies may guide interpretation of clinical data."

Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Thoracic Cancer • Triple Negative Breast Cancer • HER-2 • MFI2

Seattle Genetics antibody-drug conjugate innovation and targeted therapy programs to be featured at the AACR Virtual Annual Meeting II on June 22-24, 2020 (Businesswire) - "Seattle Genetics, Inc…announced highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020."

Clinical data • Preclinical • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer